Prevention of preeclampsia – review

Czech version

Authors: R. Vlk; J. Matěcha; V. Drochýtek
Authors‘ workplace: Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha, přednosta prof. MUDr. L. Rob, CSc.
Published in: Ceska Gynekol 2015; 80(3): 229-235

Overview

Preeclampsia is a serious condition that affects about five percent of pregnant women. The disorder itself or related complications are responsible for a significant percentage of maternal and fetal morbidity, even in developed countries. Although our understanding of etiology is still limited, the possibility of detecting and evaluating certain angiogenic factors by the end of the first trimester gives food for thought about prospects for preeclampsia prevention. Secondary prevention is currently based mostly on the effort to pharmacologically affect the spiral artery transformation and development of the abnormal placental microcirculation which lead to clinical symptoms of preeclampsia. The preventive treatment options are narrow. Greatest effect was noted with acetylsalicylic acid medication in the at-risk population. The dose of 75–150 mg per day is considered optimal. The treatment should start before the 16th gestational week; later initiation of therapy is associated with considerably smaller effect. The incidence of the early-onset preeclampsia (<34th gestational week) can be reduced up to 50% while preventive treatment affects the late-onset preeclampsia only minimally. Calcium supplementation is effective only in women with low calcium intake. Question for the future as well as subject of several studies is a clinical significance of low molecular weight heparin and sildenafil.

Keywords:
preeclampsia, prevention, aspirin, acetylsalicylic acid, heparin, antioxidants, sildenafil

Sources

1. Askie, LM., Duley, L., Henderson-Smart, DJ., Stewart, LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet, 2007, 369, p. 1791–1798.

2. Associazione Italiana Preeclampsi (AIPE), Italian branch of ISSHP. Linee guida per il managent preclampsi dell´ipertensione in gravidanza, 2007.

3. Atallah, A., Hofmeyr, G., Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev, 2006, 1, CD001059.

4. Belizan, JM., Villar, J., Repke, J. The relationship between calcium intake and pregnancy-induced hypertension: up-todate evidence. Am J Obstet Gynecol, 1988, 158, 4, p. 898–902.

5. Bujold, E., Roberge, S., Nicolaides, KH. Lowe-dose aspirin for prevention of averse outcomes related to abnormal placentation. Prenat Diagn, 2014, 34, p. 642–648.

6. Bujold, E., Tapp, S., Audibert, F., et al. Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for future randomized trials. J Obstet Gynaecol Can, 2011, 33, 5, p. 480–483.

7. Bujold, E., Roberge, S., Lacasse, Y., et al. Preventioin of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol, 2010, 116, p. 402–414.

8. Bujold, E., Morency, AM., Roberge, S., et al. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can, 2009, 31, 9, p. 818–826.

9. Caritis, S., Sibai, B., Hauth, J., et al. Low dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med, 1998, 338, p. 701–705.

10. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet, 1994, 343, p. 619–629.

11. Conde-Agudelo, A., Romero, R., Kusanovic, JP., Hassan, SS. Supplementation with vitamins C and E during pregnancy for the prevention of pre-eclampsia and other adverse maternal and perinatal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol, 2011, 204, p. 503.e1–503.e12.

12. Dalby-Salvig, J., Olsen, SF., Secher, NJ. Effects of fish oil supplementation in late pregnancy on blood pressure: a randomised controlled trial. Br J Obstet Gynecol, 1996, 103, p. 529–533.

13. Dekker, G., Sibai, B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet, 2001, 357, p. 209–215.

14. Deutsche Gesellshaft fuer Gyneklogie und Geburtshilfe (DGGG). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen, 2010 (register 015/018).

15. Dood, JM., McLeod, A., Windrim, RC., Kingdom, J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev, 2013, 7, CD006780.

16. Duley, L., Henderson-Smart, DJ., Meher, S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev, 2010, 4, CD005548.

17. Duley, L., Gülmezoglu, AM., Henderson-Smart, DJ., Chou, D. Magnesium sulfate and other anticonvulsants for women with preeclampsia. Cochrane Database Syst Rev, 2010, 11, CD000025.

18. Duley, L., Henderson-Smart, DJ., Meher, S., King, JF. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev, 2007, 2, CD004659.

19. Duley, L., Henderson-Smart, DJ., Meher, S. Altered dietary salt for preventing preeclampsia, and its complications. Cochrane Database Syst Rev, 2005, 4, CD005548.

20. Duley, L., Henderson-Smart, DJ., Knight, M., King, L. Antiplatelet drugs for prevention of preeclampsia and its consequences: systematic review. Br Med J, 2001, 322, p. 329–333.

21. Ganzevoort, W., Alfirevic, Z., von Dadelszen, P., et al. STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev, 2014, 3, p. 23.

22. George, EM., Palei, AC., Dent, EA., Granger, JP. Sildenafil attenuates placental ischemia-induced hypertension. Am J Physiol Regul Integr Comp Physiol, 2013, 305, p. 397–403.

23. Heyborne, K. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol, 2000, 183, p. 523–528.

24. Hofmeyr, GJ., Lawrie, TA., Atallah, AN., Duley, L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev, 2010, 8, CD001059.

25. Chappell, L., Seed, P., Briley, A., et al. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: a randomised trial. Lancet, 1999, 354, p. 810–816.

26. Chiaffarino, F., Parazzini, F., Paladini, D., et al. A small randomised trial of low-dose aspirin in women at high risk of preeclampsia. Eur J Obstet Gynecol Reprod Biol, 2004, 112, p. 142–144.

27. Italian study of aspirin in pregnancy. Low dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy induced hypertension. Lancet, 1993, 341, p. 396–400.

28. Kaandorp, S., Di Nisio, M., Goddijn, M., Middeldorp, S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009, 1, CD004734.

29. Karasu, E., Kayacan, N., Sadan, G., Dinc, B. Endothelial dysfunction in the human umbilical artery due to preeclampsia can be prevented by sildenafil. Clin Exp Hypertens, 2012, 34, p. 79–85.

30. Kingdom, JC., Walker, M., Proctor, LK., et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost, 2011, 9, p. 1483–1492.

31. Levine, RJ., Hauth, JC., Curet, LB., et al. Trial of calcium to prevent preeclampsia. N Engl J Med, 1997, 337, p. 69–75.

32. Lowe, S., Brown, M., Dekker, G., et al. Guidelines for the management of hypertensive disorders of pregnancy. Aust NZ J Obstet Gynecol, 2009, 49, p. 242–246.

33. Magee, LA., Helewa, M., Moutquin, JM., von Dadelszen, P. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy, SOGC Clinical Practice Guideline, 2008, JOGC No. 206.

34. Makrides, M., Duley, L., Olsen, SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev, 2006, 3, CD003402.

35. Marcoux, S., Brisson, J., Fabia, J. Calcium intake from dairy products and supplements and the risk of preeclampsia and gestational hypertension. Am J Epidemiol, 1991, 133, p. 1266–1272.

36. Mattar, F., Sibai, BM. Prevention of preeclampsia. Semin Perinatol, 1999, 23, p. 58–64.

37. McCance, DR., Holmes, VA,, Maresh, MJ., et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomized placebo-controlled trial. Lancet, 2010, 376, p. 259–266.

38. Meher, S., Duley, L. Progesterone for preventing preeclampsia and its complications. Cochrane Database Syst Rev, 2011, 4, CD006175.

39. Meher, S., Duley, L. Rest during pregnancy for preventing pre-eclampsia and its complications in women with normal blood pressure. Cochrane Database Syst Rev, 2010, 2, CD005939.

40. Meher, S., Duley, L. Garlic for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2006, 3, CD006065.

41. Olsen, S., Secher, NJ., Tabor, A., et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Br J Obstet Gynecol, 2000, 107, p. 382–395.

42. Panda, S., Das, A., Md Nowroz, H. Sildenafil citrate in fetal growth restriction. J Reprod Infertil, 2014, 15, 3, p. 168–169.

43. Patrelli, TS., Dall'asta, A., Gizzo, S., et al. Calcium supplementation and prevention of preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med, 2012, 25, p. 2570–2574.

44. Penka, M., Binder, T., Dulíček, P. Doporučené postupy antitrombotického zajištění těhotných podle rizika tromboembolické nemoci (TEN). Česká Gynekologie 2013, 78, Suppl., s. 34–36.

45. Poston, L., Briley, AL., Seed, PT., et al. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial). Lancet, 2006, 367, p. 1145–1154.

46. Prise en charge multidusciplinaire de la préeclampsie. Recommandations formalisées d´experts communes. Ann Fran Anest Reanimat, 2009, 28, p. 275–281.

47. Roberge, S., Villa, P., Nicolaides, K., et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther, 2012, 31, p. 141–146.

48. Rumbold, A., Duley, L., Crowther, CA., Haslam, RR. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev, 2008, 1, CD004227.

49. Sibai, BM., Caritis, S., Thom, E., et al. Prevention of preeclampsia with low-dose aspirin in healthy nulliparous pregnant women. N Engl J Med, 1993, 329, p. 1213–1218.

50. Silagy, CA., Neil, HA. A meta-analysis of the effect of garlic on blood pressure. J Hypertension, 1994, 12, p. 463–468.

51. Teran, E., Hernandez, I., Nieto, B., et al. Coenzyme Q10 supplementation during pregnancy reduced the risk of preeclampsia. Int J Gynecol Obstet, 2009, 105, p. 43–45.

52. Vainio, M., Kujansuu, E., Iso-Mustajarvi, M., Maenpaa, J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br J Obstet Gynecol, 2002, 109, p. 161–167.

53. Villar, J., Purwar, M., Merialdi, M., et al. WHO multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. Brit J Obstet Gynecol, 2009, 116, p. 780–788.

54. Villar, J., Abdel-Aleem, H., Merialdi, M., et al. WHO randomised trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol, 2006, 194, p. 639–649.

55. Visintin, C., Mugglestone, MA., Almerie, MQ., et al. Guideline Development Group – management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ, 2010, 340, p. 2207.

56. Wen, SV., Chen, XK., Redger, M., et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol, 2008, 198, p. 45–47.

57. Wareing, M., Myers, J., Ohara, M., et al. Effects of phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol, 2004, 190, p. 1283–1290.

58. Weissgerber, TL., Wolfe, L., Davies, GAL. The role of regular physical activity in preeclampsia prevention. Med Scien Sports Exercise, 2004, 36, 12, p. 2024–2031.

59. Wojtowicz, A., Undas, A., Huras, H., et al. Aspirin resistence may be associated with adverse pregnancy outcomes. Neuro Endocrinol Lett, 2011, 32, p. 334–339.

60. Yu, C., Papageorghiou, A., Parra, M., et al. Randomized controlled trial using low-dose aspirin in the prevention of preeclampsia in women with abnormal uterine artery Doppler at 23 weeks gestation. Ultrasound Obstet Gynecol, 2003, 22, p. 233–239.